University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain.
Department of Hematology, University Hospital Dr. José Molina Orosa, Lanzarote, Canary Islands, Palmas, Spain.
Blood Cancer J. 2023 Mar 20;13(1):40. doi: 10.1038/s41408-023-00807-9.
Multiple myeloma (MM) patients with t(11;14) present unique biological features and their prognosis is not well established. We report a retrospective study of 591 MM patients, 17.3% of whom had t(11;14). It was designed to determine the prognostic impact of this abnormality and the effect of novel agents on the response and outcomes. Three groups were established based on their cytogenetics: (1) t(11;14); (2) high-risk chromosomal abnormalities; and (3) standard risk (SR). After 80.1 months (1.2-273.8 months) of follow-up, no differences were observed in overall survival (OS) between the t(11;14) and SR groups (75.8 vs. 87.2 months; P = 0.438). Treatment of MM t(11;14) with novel agents did not improve their overall response rate (ORR) or complete response (CR) compared with those who received conventional therapy (ORR: 87.2 vs. 79.5%, P = 0.336; CR: 23.4 vs. 12.8%, P = 0.215). This effect translated into a similar PFS (39.6 vs. 30.0 months; P = 0.450) and OS (107.6 vs. 75.7 months; P = 0.175). In summary, MM t(11;14) patients did not benefit from the introduction of novel agents as much as SR patients did, indicating that other therapies are needed to improve their outcomes.
多发性骨髓瘤（MM）伴 t（11；14）患者具有独特的生物学特征，其预后尚不确定。我们报告了一项对 591 例 MM 患者的回顾性研究，其中 17.3%的患者存在 t（11；14）。本研究旨在确定这种异常的预后影响以及新型药物对反应和结局的影响。根据细胞遗传学将患者分为三组：（1）t（11；14）；（2）高危染色体异常；（3）标准风险（SR）。在 80.1 个月（1.2-273.8 个月）的随访后，t（11；14）组与 SR 组的总生存（OS）无差异（75.8 与 87.2 个月；P=0.438）。与接受常规治疗的患者相比，MM t（11；14）患者使用新型药物治疗并未提高其总体缓解率（ORR）或完全缓解（CR）（ORR：87.2 与 79.5%，P=0.336；CR：23.4 与 12.8%，P=0.215）。这一效果转化为相似的无进展生存期（PFS）（39.6 与 30.0 个月；P=0.450）和 OS（107.6 与 75.7 个月；P=0.175）。总之，MM t（11；14）患者并没有像 SR 患者那样从新型药物的引入中获益，这表明需要其他治疗方法来改善他们的预后。
